SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-041325
Filing Date
2024-05-09
Accepted
2024-05-09 16:20:50
Documents
15
Period of Report
2024-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0205626-8k_nektar.htm   iXBRL 8-K 24800
2 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL R ea020562601ex99-1_nektar.htm EX-99.1 66202
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2044
  Complete submission text file 0001213900-24-041325.txt   275209

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nktr-20240509.xsd EX-101.SCH 3009
5 XBRL LABEL FILE nktr-20240509_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE nktr-20240509_pre.xml EX-101.PRE 22355
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0205626-8k_nektar_htm.xml XML 3565
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

IRS No.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 24931044
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)